ZEMBRACE SYMTOUCH (AUTOINJECTOR) Drug Patent Profile
Which patents cover Zembrace Symtouch (autoinjector), and when can generic versions of Zembrace Symtouch (autoinjector) launch?
Zembrace Symtouch (autoinjector) is a drug marketed by Tonix Meds and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in ZEMBRACE SYMTOUCH (AUTOINJECTOR) is sumatriptan succinate. There is one drug master file entry for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zembrace Symtouch (autoinjector)
A generic version of ZEMBRACE SYMTOUCH (AUTOINJECTOR) was approved as sumatriptan succinate by HIKMA on February 6th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ZEMBRACE SYMTOUCH (AUTOINJECTOR)?
- What are the global sales for ZEMBRACE SYMTOUCH (AUTOINJECTOR)?
- What is Average Wholesale Price for ZEMBRACE SYMTOUCH (AUTOINJECTOR)?
Summary for ZEMBRACE SYMTOUCH (AUTOINJECTOR)
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | ZEMBRACE SYMTOUCH (AUTOINJECTOR) at DailyMed |
-patent-expirations.png "ZEMBRACE SYMTOUCH (AUTOINJECTOR) drug patent expirations")
Pharmacology for ZEMBRACE SYMTOUCH (AUTOINJECTOR)
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
US Patents and Regulatory Information for ZEMBRACE SYMTOUCH (AUTOINJECTOR)
ZEMBRACE SYMTOUCH (AUTOINJECTOR) is protected by three US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tonix Meds | ZEMBRACE SYMTOUCH (AUTOINJECTOR) | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223-001 | Jan 28, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tonix Meds | ZEMBRACE SYMTOUCH (AUTOINJECTOR) | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223-001 | Jan 28, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tonix Meds | ZEMBRACE SYMTOUCH (AUTOINJECTOR) | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223-001 | Jan 28, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZEMBRACE SYMTOUCH (AUTOINJECTOR)
See the table below for patents covering ZEMBRACE SYMTOUCH (AUTOINJECTOR) around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Brazil | 112018002433 | composição farmacêutica para tratamento da enxaqueca | ⤷ Start Trial |
| Canada | 2994748 | COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE) | ⤷ Start Trial |
| China | 107921023 | 用于治疗偏头痛的包含舒马曲坦的药物组合物 (Pharmaceutical composition comprising sumatripan for treating migraine) | ⤷ Start Trial |
| European Patent Office | 3331524 | COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE) | ⤷ Start Trial |
| Mexico | 2018001528 | COMPOSICION FARMACEUTICA QUE COMPRENDE SUMATRIPTAN PARA TRATAMIENTO DE MIGRAÑA. (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE.) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017023361 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch